MedPath

Procedural Sedation for Pediatric Patients With Spinal Muscular Atrophy

Completed
Conditions
Anesthesia
Child, Only
Muscular Atrophy, Spinal
Registration Number
NCT05291962
Lead Sponsor
Ankara City Hospital Bilkent
Brief Summary

Background and Aim: Spinal muscular atrophy (SMA) is a neuromuscular disease characterized by progressive symmetrical weakness and atrophy of proximal muscles causing from degeneration of anterior horn cells of spinal cord. Nusinersen must be administered intrathecally and this treatment is specially for spinal muscular atrophy. Procedural sedation is commonly enough for intrathecal treatment in children. In this retrospective study, the investigators aimed to present our experience in procedural sedation for the intrathecal treatment of patients with SMA 1,2 and 3 in our hospital.

Detailed Description

Design: This research is a retrospective obsevational study. Methods: After approval Institutional Review Board, data from anesthesia charts and electronic medical records of 14 patients with SMA type I, II and III who underwent procedural sedation,such as; the demographics data of the patients (age, gender, weight, American Society of Anesthesiologist (ASA) Physical Status), which anesthetic agent was used and their doeses, during of anesthesia, presence of scoliosis, by whom the procedure was performed etc. was reviewed. All our patients with SMA type II and III who underwent intrathecal treatment are given sedation with different combination of anesthetic agent. Due to peripheral intravenous line was placed previously, intravenous induction was performed in all of our patients For procedural sedation, anesthesiologists used different combination of midazolam, ketamine, propofol, fentanyl or remifentanyl, depending on the patient's requirement. They were oxygenated with a face mask or nasal cannula while their spontaneous breathing continues. All patients were recovered in the recovery room.

Statistical analysis: The data were analyzed by using SPSS Statistics Software (SPSS 24, Chicago, IL, USA) Descriptive statistics were used in this study. Mean and standart deviation were calculated for Age (year), Weight (kilogram), Midazolam Dose (mg/kg), Fentanyl Dose (mcg/kg), Remifentanyl Dose (mcg/kg), Propofol Dose (mg/kg), Ketamine Dose (mg/kg) and Length of Stay in Recovery Room (minute) and frequency analysis were made for the number of intervention.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
14
Inclusion Criteria
  • Pediatric patients younger than 18 years old with SMA 1,2 and 3 who were to undergo intrathecal Nusinersen treatment were included in this study.
Exclusion Criteria
  • Patients whose procedures were performed under fluoroscopic guidance in the radiology unit were excluded from the study because their procedures were performed in another hospital.
  • Patients without a diagnosis of SMA

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Procedural sedation4 years (The data of the patients were retrospectively analyzed between July 2017 and December 2021.)

The number of pediatric patients with SMA I,II and III who underwent intrathecal treatment required procedural sedation

Anesthetics use4 years (The data of the patients were retrospectively analyzed between July 2017 and December 2021.)

The anesthetic agents and their doses that used during procedure

Age4 years (The data of the patients were retrospectively analyzed between July 2017 and December 2021.)

Age in year

Gender4 years (The data of the patients were retrospectively analyzed between July 2017 and December 2021.)

Gender as female/male

Weight4 years (The data of the patients were retrospectively analyzed between July 2017 and December 2021.)

Weight in kilograms

American Society of Anesthesiologists (ASA) physical status4 years (The data of the patients were retrospectively analyzed between July 2017 and December 2021.)

ASA score

Type of SMA4 years (The data of the patients were retrospectively analyzed between July 2017 and December 2021.)

SMA I, SMA II and SMA III

Secondary Outcome Measures
NameTimeMethod
Presence of scoliosis4 years The data of the patients were retrospectively analyzed between July 2017 and December 2021.)(

Yes or no

How many times intrathecal treatment was performed for each patient4 years The data of the patients were retrospectively analyzed between July 2017 and December 2021.)

The number of intrathecal treatments was administered for each patient over 4 years was recorded.

By whom the procedure was performed4 years The data of the patients were retrospectively analyzed between July 2017 and December 2021.)

It was recorded who performed the lumbar puncture procedure from a neurologist, neurosurgeon, or anesthesiologist.

Length of time spent in recovery room4 years The data of the patients were retrospectively analyzed between July 2017 and December 2021.)

Recovery time in minutes

Trial Locations

Locations (1)

Feyza Sever

🇹🇷

Ankara, Çankaya, Turkey

© Copyright 2025. All Rights Reserved by MedPath